ImmunityBiovsThermo Fisher Scientific

IBRX and TMO stock compared: price, dividend, valuation and results, from SEC filings.

IBRX

ImmunityBio, Inc.

$6.02

Value $6.2B

-0.82%
IBRX's page

TMO

Thermo Fisher Scientific Inc

$700.22

Value $260B

+0.11%
TMO's page

ImmunityBio (IBRX) has a market value of $6.2B and Thermo Fisher Scientific (TMO) $260B. Over the last year, with dividends, IBRX moved +192.2% and TMO +19.5%. Dividend yield: IBRX none, TMO 0.26%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    IBRX$6.2B

    TMO$260B

    TMO is 42 times IBRX

  • Revenue, 12 months

    IBRX$183M

    TMO$47.4B

    TMO is 259 times IBRX

  • Net income, 12 months

    IBRX-$1.1B

    TMO$7.1B

  • Operating margin

    IBRX-150.2%

    TMO17.9%

    168.1 points apart

  • ROIC

    IBRX–

    TMO8.2%

  • P/E

    IBRX–

    TMO36.8

  • Dividend yield

    IBRX0.0%

    TMO0.3%

    0.3 points apart

  • 5-year return

    IBRX-22.0%

    TMO+11.8%

    33.8 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

IBRX-22.0%

TMO+11.8%

5010020222023202420252026
Returns by period
PeriodIBRXWith dividendsTMOWith dividends
1 year since November 12, 2025+192.2%Price +192.2%+19.5%Price +19.1%
3 years since November 13, 2023+75.0%+20.5% a yearPrice +75.0%+58.8%+16.7% a yearPrice +57.3%
5 years since November 12, 2021-22.0%-4.9% a yearPrice -22.0%+11.8%+2.3% a yearPrice +10.2%
10 years since November 15, 2016-19.7%-2.2% a yearPrice -19.7%+384.5%+17.1% a yearPrice +371.0%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

IBRXImmunityBioTMOThermo Fisher Scientific

Valuation

IBRXTMO
Valuation
Price$6.02$700.22
Market value$6.2B$260B
Enterprise value (EV)–$295B
P/E–36.8
P/E, 5-year median–32.7
P/B–4.8
EV/EBIT–34.9
Free cash flow yield–2.9%

Results and growth

IBRXTMO
Results and growth
Revenue, 12 months$183M$47.4B
Net income, 12 months-$1.1B$7.1B
Free cash flow, 12 months-$297M$7.6B
Earnings per share, 12 months-$1.08$18.96
Revenue growth, year on year668.3%3.9%
Revenue growth a year, past+184.8%over 5 years+6.7%over 5 years
EPS growth a year, past–+2.1%over 5 years

Margins and returns on capital

IBRXTMO
Margins and returns on capital
Gross margin98.8%–
Operating margin-150.2%17.9%
Net margin-607.8%14.9%
ROIC–8.2%
ROE–13.4%

Balance sheet

IBRXTMO
Balance sheet
Cash$334M$6.1B
Total debt–$41.4B
Net debt / EBITDA–3.7
Interest cover-4.5×5.5×

Dividends and buybacks

IBRXTMO
Dividends and buybacks
Dividend yield–0.3%
Dividend per share, 12 months–$1.84
Dividend growth a year, past–+14.3%over 5 years
Buyback yield–1.2%
Shareholder yield–1.4%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: IBRX or TMO

Didn't find what you were looking for?

Ask us
Which is bigger, ImmunityBio or Thermo Fisher Scientific?

By market value, Thermo Fisher Scientific ($260B) is about 42.0 times ImmunityBio ($6.2B), at today's prices.

How did IBRX and TMO stock do over the last 10 years?

Since November 15, 2016, IBRX's price moved -19.7% and TMO's +371.0%. With dividends: IBRX -19.7% (-2.2% a year), TMO +384.5% (+17.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, IBRX or TMO?

The dividend yield at today's price is none for ImmunityBio and 0.26% for Thermo Fisher Scientific. Over the last twelve months they paid – and $1.84 per share.

Which has the higher profit margins, ImmunityBio or Thermo Fisher Scientific?

Over the last twelve months, the net margin was -607.8% for ImmunityBio and 14.9% for Thermo Fisher Scientific, and the operating margin -150.2% and 17.9%. Revenue was $183M and $47.4B.

Which is the better investment, ImmunityBio or Thermo Fisher Scientific?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.